Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

Icatibant has been studied for the treatment of acute attacks of hereditary angioedema
(HAE), an autosomal dominant disorder characterized by recurrent and self-limiting episodes
of edema of the skin, larynx, and gastrointestinal tract. The most serious manifestation of
an HAE attack is laryngeal edema, causing obstruction of the upper airways that may lead to
death by asphyxiation if undiagnosed and/or untreated.

Icatibant has been approved in over 40 countries around the world including the United
States (US) and Europe for the treatment of acute attacks of hereditary angioedema (HAE) in
adults. This study is being conducted to evaluate the safety and tolerability of icatibant
in a Japanese population and to evaluate whether race/ethnicity impacts the pharmacokinetics
of icatibant after single subcutaneous injection.

This is an open-label, single-arm study that will enroll at least 12 Japanese subjects (in
order to have 12 subjects complete the study), age 18-55 years inclusive. All subjects will
receive a single subcutaneous injection of 30mg icatibant. The study will be conducted at 1
site in the US. The study will consist of a Screening Period, a Treatment Period, and a
Follow-Up Period.

Inclusion Criteria:

1. Healthy male and female volunteers, 18 to 55 years of age, inclusive; healthy status
defined as absence of clinically significant findings in medical history or screening
assessments

2. Japanese; defined as born in Japan, lived outside of Japan for no more than 10 years,
and having Japanese parents and Japanese maternal and paternal grandparents

3. Body mass index of 18 to 28 kg/m2, inclusive

Exclusion Criteria:

1. History of, or current, clinically significant disease and/or abnormalities

2. Smoking habit in excess of 5 cigarettes per day or the equivalent within 30 days of
Day 1 or inability to refrain from smoking during the study confinement period

3. Subject has current abnormal thyroid function, as defined as abnormal screening
thyroid stimulating hormone (TSH) and free thyroxine (T4). Treatment with a stable
dose of thyroid medication for at least 12 weeks is permitted

4. History of drug allergy or other allergy that, in the opinion of the investigator,
contraindicates participation

5. Male subjects who consume more than 21 units of alcohol per week or 3 units per day.
Female subjects who consume more than 14 units of alcohol per week or 2 units per
day. (1 alcohol unit =1 beer or =1 wine (5oz/150mL) or =1 liquor (1.5oz/40mL) or
=0.75oz alcohol)

6. Routine consumption of more than 2 units of caffeine per day or subjects who
experience caffeine withdrawal headaches. (1 caffeine unit is contained in the
following items: one 6oz (180mL) cup of coffee, two 12oz (360mL) cans of cola, one
12oz cup of tea, three 1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola
are not considered to contain caffeine)

7. Current use of any medication (including over-the-counter, herbal, or homeopathic
preparations) with the exception of female hormonal replacement therapy or hormonal
contraceptives. Occasional use of over-the-counter doses of ibuprofen or
acetaminophen for minor self-limited pain (eg, headaches) is also acceptable.
Current use is defined as use within 7 days of the first dose of investigational
product\

8. Pregnant or lactating females